Q-omics provides the consensus-scored ZNF670-ZNF695 profile across patient tissues and cancer cell-line models. ZNF670-ZNF695 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF670-ZNF695 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ZNF670-ZNF695 RNA expression shows 17,177 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, BLCA, and UVM as cancer lineages where ZNF670-ZNF695 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF670-ZNF695 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF670-ZNF695 survival associations across molecular data types. ZNF670-ZNF695 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF670-ZNF695 RNA expression–survival associations across cancer types. High ZNF670-ZNF695 expression shows unfavorable associations in KICH, ACC, MESO, KIRP, UCEC and SARC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF670-ZNF695 RNA expression.
This table summarizes ZNF670-ZNF695 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF670-ZNF695. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF670-ZNF695 shows higher tumor expression in BLCA, COAD, LUAD, HNSC, STAD and LUSC. The BLCA box plot shows higher ZNF670-ZNF695 RNA expression in tumor versus normal tissue (log2 FC = +0.346, t-test p < 0.001).
This table shows molecular features associated with ZNF670-ZNF695 in patient tissues and cancer cell lines. In patient samples, ZNF670-ZNF695 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF670-ZNF695 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
